Precision Medicine
A PROMISING FUTURE FOR PATIENT OUTCOMES
Precision medicine has the potential to provide a tailored approach to care, for improved patient outcomes and lower costs.

The National Institutes of Health defines precision medicine as an “emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.”

This type of personalized medicine—with targeted treatment and prevention plans—has the potential to improve early disease detection and prevent progression, while improving healthcare efficiency, quality, access, and affordability. The “one-size-fits-all” approach to treatment can be ineffective and expensive. By understanding which patients are likely to benefit from a specific treatment intervention, outcomes may often be improved while lowering costs and reducing side effects.

Five key areas of precision medicine have been identified as particularly promising:

- **DIAGNOSIS/PROGNOSIS**: to evaluate certain subtypes of a disease or the distinctive characteristics of a health condition.
- **TREATMENT PREDICTION**: to determine whether a patient, infection, or tumor with certain characteristics may respond to a specific treatment.
- **DOSING**: to analyze the appropriate amounts or strengths of treatment to give to a certain individual.
- **SAFETY**: to anticipate adverse events and reactions in certain subpopulations of patients.
- **MONITORING**: to track and observe a patient’s response to treatment, partly to assess if any modifications to treatment may be necessary.

Precision medicine allows physicians and researchers to more accurately predict which drugs, treatment, and prevention strategies for a disease may work best in certain subpopulations, avoiding costly trial-and-error methods.
Genome sequencing, the cornerstone of precision medicine, continues to advance.

Sequencing of the human genome has greatly accelerated the process of linking specific gene variants with disease, which is likely to expand as sequencing plays a larger role in healthcare and delivery of the appropriate and most efficacious treatments.

### TECHNOLOGICAL INNOVATION IS SPEEDING GENOMIC SEQUENCING FORWARD

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Genome sequencing begins in the U.S.⁵</td>
<td>Complete sequencing of human genome accomplished through the Human Genome Project⁶</td>
<td>An estimated 228,000 human genomes have been completely sequenced worldwide by the end of this year⁷</td>
<td><em>All of Us</em> Research Program (formerly the Precision Medicine Initiative Cohort Program) launched to gather individual health data from &gt;1 million U.S. participants, who will share genetic data, biological samples, and lifestyle information to fill the gap in our understanding of human genetic variation²,⁸,⁹</td>
</tr>
</tbody>
</table>
Clinical diagnostics and biomarkers help identify appropriate treatment options, but challenges remain

Research & development pipelines embrace precision medicine
With the rise of precision medicine, diagnostic and biomarker tests are identifying appropriate treatments and drug therapies for individual patients earlier in the disease course. The focus on precision medicine in product development pipelines is also expanding, indicating a growing commitment to precision medicine in the biopharmaceutical industry.

As of 2016, 132 personalized medicines with specific biomarkers included in product labeling were on the market.2

The FDA has approved 29 companion diagnostic tests that are required for the use of certain cancer treatments. Other complementary diagnostics can aid in the risk-benefit decision making regarding the use of a particular therapy.10

Healthcare stakeholders are navigating regulatory, coverage, and reimbursement changes
Recent trends indicate growth and uptake of precision medicine; however, regulatory and coverage challenges remain. Draft FDA guidance for the development of companion diagnostics was published in 2016, indicating motion toward adapting to new developments in precision medicine. Coverage and reimbursement challenges also exist as payers seek evidence of the clinical and economic impact of precision medicine in practice. Value-based payment models, value assessment frameworks, and payment and coding standards may all influence the adoption of precision medicine in clinical practice.2

>25% of new FDA drug approvals in 2016 were personalized medicines.2

~40% of drugs in the development pipeline include biomarkers in their R&D design.2
Select types of molecular diagnostic tests

The identification and measurement of changes in DNA, RNA, or specific genes are accomplished using molecular tests, which analyze organisms at the molecular level. Molecular tests often focus on single genes or mutations or gene by-products, such as proteins.

**Fluorescence and flow cytometry** — Early measurements of DNA used ultraviolet absorption methods to identify areas of interest. Fluorescence began to be used in combination with flow cytometry methods, which suspend particles in fluid for analysis.

- Flow cytometry and molecular genomics have been integral to the diagnosis of hematologic malignancies.

**DNA and sequencing tools** — Some testing tools manipulate (cut and copy) DNA material. This allows scientists to “cut” DNA strands at specific places using enzymes and produce fragments that they can separate and reproduce.

- Next-generation sequencing (NGS) techniques are rapid and automated. This sequencing process is important in lung cancers. The identification of oncogenic drivers has redefined how these illnesses are described and treated.

**Fluorescence in situ hybridization (FISH)** — FISH is a method of detecting mutations, deletions, and other genetic changes on chromosomes. A fluorescent tag is added to a complementary sequence of DNA or RNA that binds, or hybridizes, to a chromosome and can be seen using fluorescence microscopy.

- FISH-based testing has been in the mainstay of HER2-gene testing in breast cancer and in the selection of anti-HER2-targeted therapies.

**Microarray technology, DNA amplification, and polymerase chain reaction (PCR)** — Multiple tests of DNA or RNA can now be performed at the same time using a microarray analysis platform consisting of thousands of different DNA sequences. Microarrays of DNA depend on DNA amplification by PCR, which replicates strands by many orders of magnitude for analysis.

- PCR has applications in infectious disease diagnosis, and in the diagnosis and treatment planning for cancers, such as non–small-cell lung cancer.
Evolving clinical trial designs match patients with experimental therapies

Researchers are using two types of clinical trial designs to improve the matching of genetically profiled cancer patients to beneficial experimental therapies. These trial designs are not without challenges — one being the difficulty in finding adequate numbers of patients with the same cancer subgroups.

Umbrella trials enroll patients with one specific tumor type, profile the tumor, and treat with different therapies (each targeting a different biomarker profile) in the same trial.

Basket trials group together patients with several different types of cancers, but with a similar biomarker profile in their tumors so they can receive a treatment that targets those molecular drivers.
New clinical trials explore the promise of precision medicine

Trials sponsored by the National Cancer Institute (NCI) are advancing precision medicine research

With support from the NCI, scientists are pursuing new technologies and collaborations, and are conducting new kinds of clinical trials to explore the promise of precision medicine. A new precision medicine strategy is being tested through genotype-to-phenotype and phenotype-to-genotype research initiatives. Genotype-to-phenotype trials screen for molecular features that may predict treatment response to a drug with a particular mechanism of action. Phenotype-to-genotype trials use retrospective genotype analysis of a patient’s tumor to discover if molecular factors may explain why the patient responded well to a particular treatment.\(^\text{17}\)

Funded in part by the Precision Medicine Initiative, the NCI-supported precision medicine trials include the Lung-MAP, ALCHEMIST, NCI-MPACT, and NCI-MATCH studies. The NCI-MATCH (Molecular Analysis for Therapy Choice) study is unique in assigning adult patients to targeted treatments based on the genetic abnormalities in their tumor, regardless of cancer type.\(^\text{17,18}\) The expanded availability of tumor sequencing through commercial vendors has given patients broader access to information about clinical trials, in turn allowing NCI-MATCH to access thousands of patients who would not otherwise be available for screening and enrollment. These developments have increased participation in the rare variant arms of clinical trials.\(^\text{17}\)

Genentech is committed to bringing innovation to clinical trial design

Genentech is implementing innovative clinical trial designs that aim to bring individualized medicine to each patient by simultaneously\(^\text{19}\):

- Testing a single drug in multiple diseases
- Testing several drugs against a single disease
- Condensing the traditional 3-phase clinical trial into a fluid, adaptive process

Spotlight on innovation and partnerships to advance cancer treatment\(^\text{19}\)

Flatiron Health was founded on the premise of leveraging big data to help researchers discover more effective therapies and better match cancer patients with life-saving treatments. The company recognized that much of the collected real-world data were stored across thousands of disconnected care settings such as medical centers, hospitals, and community clinics.\(^\text{20}\) Through its OncoCloud™ platform, Flatiron captures real-world data from cancer patients who are not in clinical trials, transforming previously unstructured data into validated data in a registry.
The focus on precision medicine is increasing across various stakeholders

As the benefits of precision medicine are gaining traction and underlying testing costs are lowered, various healthcare stakeholders are exploring the opportunity to improve patient outcomes through this approach to care.

**BIOPHARMACEUTICAL COMPANIES | R&D PIPELINE**
- The number of personalized medicines has increased steadily since 2008\(^2\)
- R&D investment in precision medicine is anticipated to increase by 33% in the next 5 years\(^2\)
- Of the 74 new molecular entities in the Roche clinical pipeline, 30 are personalized healthcare products\(^{19}\)

**REGULATORS AND POLICY MAKERS | GUIDELINES AND APPROVALS**
- A 2016 perspective highlighted the FDA’s belief that “the desire to provide earlier access to highly effective drugs should encourage further use of seamless expansion-cohort trials, particularly as drugs with unprecedented levels of efficacy advance into clinical trials”\(^{21}\)
- The FDA released “Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product” in July 2016. This draft guidance assists therapeutic product and in vitro diagnostic device sponsors with the development process\(^{10}\)
- May 2017 marked the first time the FDA granted accelerated approval to a cancer treatment (pembrolizumab) based on a common biomarker rather than the location in the body where the tumor originated\(^{22}\)

**MANAGED CARE ORGANIZATIONS (MCOs) | COVERAGE**
- Two-thirds of MCOs and more than 50% of specialty pharmacies identified balancing treatment standardization (i.e., guidelines and pathways) with personalization (i.e., molecular/biomarker testing) as one of the most pressing challenges in cancer care in 2016\(^{23}\)
- Among surveyed MCOs\(^{23}\):
  - 30% restrict drug coverage to favorable/biomarker test results
  - 28% require a PA/precertification for molecular/biomarker tests
  - 24% restrict molecular/biomarker test coverage based on evidence supporting the validity and cost effectiveness of the test
HEALTHCARE PROVIDERS | CLINICAL PRACTICE

- Oncologists are increasingly turning to precision medicine to help identify appropriate treatments for their patients\(^{23}\)
  - 76% of oncologists rated the impact of molecular biomarker testing and NGS on patient outcomes as moderate to significant when used to identify mutations for prognosis and treatment planning
  - More than 50% of oncologists frequently discuss molecular testing with their patients

PATIENTS | TREATMENT

- Continued education of patients is needed to inform consumers about precision medicine. A 2014 survey revealed that 38% of patients had heard of precision medicine, but only 16% felt they were very informed on the subject\(^{24}\)
- Major concerns identified by patients in the survey were insurance coverage, affordability, and how collected personal information would be used\(^{24}\)
- The Personalized Medicine Coalition advocates for policies and practices for patient engagement, privacy, and data protections that ensure appropriate consent and are acceptable to patients\(^2\)
The evolving healthcare environment aligns with precision medicine objectives

The shift to value-based care aligns with the goals of precision medicine: disease prevention, effective treatment, improved outcomes, and potential cost reduction.

Collective efforts across healthcare stakeholders may help advance precision medicine
The success of precision medicine is predicated on the collaboration of multiple healthcare stakeholders to pursue innovation and support the evolution of care to drive improved patient outcomes and healthcare system efficiencies.
Payer and health system organizations are exploring the use of precision medicine

Payer perspective: adapting to the rapid advancements in precision medicine

NGS-based clinical testing challenges traditional payer coverage frameworks. Many payer organizations classify NGS testing as investigational rather than medically necessary and therefore do not offer coverage. Research suggests that payer organizations may postpone evidence review of genetic and pharmacogenomic tests due to the lack of clinical study support. Oncology has been identified as a key area of growth for the clinical application of NGS and is the first area where policy solutions will be essential.25

Priority Health was the first insurer in the U.S. to implement a formal coverage policy for the use of genomic profiling for members with aggressive forms of cancer. “By covering genomic profiling in specific circumstances, we can help identify alternative and potentially more effective treatment options for those diagnosed with aggressive or difficult-to-treat cancer,” said John Fox, M.D., senior medical director and associate vice president of medical affairs at Priority Health.26 Its medical coverage policy outlines 7 specific criteria for coverage of NGS testing in the diagnosis and treatment of cancer.27

In July 2016, UnitedHealthcare released a medical policy to cover molecular profiling using NGS testing for patients with metastatic stage IV non-small cell lung cancer that met specific criteria.28

Case study: improved outcomes without increased healthcare costs

Intermountain Healthcare recently conducted a retrospective analysis of precision medicine outcomes within one region of its delivery system. The matched-cohort study assessed outcomes and total costs in patients with advanced, refractory cancer who underwent genomic testing and received targeted treatment in the precision medicine program compared with control patients receiving standard chemotherapy or supportive care. Patients in the precision medicine group had an average progression-free survival of 22.9 weeks versus 12.0 weeks in the control group. Costs in the 2 groups were similar, with per patient charges per progression-free survival week of $4,665 for the precision medicine group and $5,000 for the control group.29

NGS enables rapid review of many genes simultaneously using a single test, and it has extended the use of sequencing beyond research and into clinical practice.5
What does the future hold?

The future of precision medicine may offer unprecedented opportunities to match the right patient with the right treatment, ultimately improving outcomes for many.30

References: